Mesothelioma is a uncommon and fast moving growth where no successful therapy has been discovered even with the discovery of quite a few potential genetic targets. The late stages of MPM diagnosis and the long time that connects some exposures and diagnosis have made it difficult to comprehensively evaluate what risk factors do and the insuing molecular effects.
Many hospitals are witnessing an increasing amount of patients with mesothelioma. This gives pathologists diagnosing the patient many problems, which can be divided into those exposed in finding the differences between malignant mesothelioma and worriless changes and those experienced in setting apart cancer of the mesothelium from other forms of e-cadherin and tissue tumors that connect. IHC performs a major role in diagnosis, but it should be interpreted with due regard to the medical setting and radiological features, and with a knowledge of the broad morphological variations existing in malignant mesothelioma.
Malignant mesothelioma is a cancer affecting the serosal cavities, an anatomical site that is often affected by metastasis, predominantly from primary cancers of the breast, ovary and lung. Developments in immunohistochemistry have lead to improvement in diagnostic sensitivity and cancer of the mesothelium in regards to histological and cytological material. As of late, the authors group applied a high level of throughput technology to the identification of new flags that may aid in being able to tell the difference between malignant mesothelioma from ovarian and peritoneal serous carcinoma, tumors with closely related histogenesis and antigenic profile. Along with the improved medical devices available for cancer of the serosa diagnosis, realizing the biology of malignant mesothelioma has increased in recent years.
